Imunon (IMNN) News Today

Imunon, Inc. (NASDAQ: IMNN) experienced upward pressure on its shares following a flurry of clinical updates and strategic financing moves. Investors are reacting to encouraging trial data, funding plans and trading volatility.

• Promising ovarian cancer trial results sent shares soaring after Imunon reported strong response rates in its Phase 2 IMNN-001 study.
• Data presented at the 2025 ASCO Annual Meeting showed a median overall survival benefit of 13 months and a 3-month increase in progression-free survival for patients on IMNN-001.
• DNA-based immunotherapy IMNN-001 displayed clinically significant survival gains in advanced ovarian cancer, reinforcing the drug’s efficacy profile.
• Retail investors applauded Imunon’s decision to withdraw its public offering, citing “much better funding options” and reduced near-term dilution.
• A major corporate announcement drove a biotech stock surge, helping IMNN close the week on a high note.
• Imunon secured up to $9.75 million in a market-priced private placement—$3.25 million upfront with warrants offering another $6.5 million potential proceeds.
• Trading was halted multiple times under Nasdaq’s LULD mechanism as volatility spiked around news releases.
• The company formally withdrew its Form S-1 registration statement, postponing a planned public offering.
• DBoral Capital downgraded IMNN to a “Hold” rating, signaling caution on the company’s near-term funding strategy and valuation.

Looking ahead, investors will monitor upcoming clinical milestones in ovarian cancer and execution of Imunon’s financing plans to assess sustainability of its development runway.